Clinic Software← All companies
StageSeed
Raised$50K
Founded2023
Employees5
LocationSanta Clara, CA
About
Coredio develops a platform that estimates catheter-grade intracardiac hemodynamics for heart failure management using wearables, AI, and digital twin modeling. The platform serves health systems, cardiology care teams, and outpatient clinics, enabling remote disease monitoring through smartwatches and blood pressure cuffs without invasive procedures. Coredio has received FDA Breakthrough Device Designation and is validating its technology against catheterization at U.S. partner sites.
Product
- Value proposition
- Noninvasive, catheter-grade hemodynamic insight using wearables, AI, and digital twins to monitor heart failure patients at home or in clinic
- Target customers
- health systems, cardiology care teams, hospital networks, outpatient clinics
- Regulatory
- FDA Breakthrough Device Designation (granted)
Founders
- Yashar Vahedein — Co-Founder & CEO
- Mehdi Mortazawy — Co-Founder & CTO
Products
Coredio platformwearable-derived hemodynamic estimatesdigital twin modeling for intracardiac pressures
Key features
Noninvasive catheter-grade hemodynamic estimatesspot-check monitoring with wearablesdigital twin patient modelingvalidation against catheterizationworkflow for remote disease management
Technologies
wearable sensorsAIdigital twinsphysic-informed modeling
Integrations
EHRs / platforms / systems it integrates with
Target conditions
Heart failurecardiovascular diseasehemodynamic monitoring
Care settings
homeclinichospitals (for monitoring)
Certifications
FDA Breakthrough Device Designation
Awards
FDA Breakthrough Device Designation
Investors
MassChallenge U.S.Future of Healthcare Founder Residency ProgramPlug and Play Silicon Valley summitCaelestinusPlug and Play Travel & HospitalityPlug and Play Tech Center
News
- Coredio’s AI heart failure software secures breakthrough designation - Medical Device Network · 2026-05-29T09:56:32.000Z
- FDA sees potential in new AI software for monitoring heart failure patients · 2026-05-29T00:00:00.000Z
- FDA breakthrough status gives Coredio’s AI heart failure platform a faster regulatory path - PharmaDeviceNews · 2026-05-29T04:54:00.000Z
- Coredio’s CPSE Platform for HF Assessment Gains FDA Breakthrough Designation - Cardiac Interventions Today · 2026-05-28T00:00:00.000Z
- Coredio Receives FDA Breakthrough Device Designation for AI Heart Failure Platform - Boston Life Sciences Times · 2026-05-28T14:06:45.000Z
- FDA Grants Coredio Breakthrough Designation for AI Platform Bringing Advanced Heart Failure Assessment Beyond the Hospital - Cardiac Vascular News · 2026-05-28T13:15:00.000Z
